Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 7.01, 9.01 · 8-K

Assertio Holdings Inc.

Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 8, 2026, Assertio Holdings, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that on May 7, 2026, in connection with the previously announced entry into an Amended and Restated Agreement and Plan of Merger, dated as of May 1, 2026 (the “Merger Agreement”), by and among the Company, Garda Therapeutics, Inc., a Delaware corporat…

Filed May 8, 2026Accepted May 8, 2026, 8:13 AM EDTCIK 1808665Accession 0001104659-26-057577
Share

Company context

Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit www.assertiotx.com.

Historical securities (1)

Recent company filings

  1. 15-12G filingJul 31, 2026
  2. 25-NSE - filed by Nasdaq Stock Market LLC regarding Assertio Holdings, Inc.Jul 7, 2026
  3. 15-12G filingJun 26, 2026
  4. EFFECT filingJun 17, 2026
  5. EFFECT filingJun 17, 2026

Registered securities in this filing

ASSERTIO HOLDINGS, INC. · 8-K · Filed 2026-05-08

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
ASRT
Exchange
NASDAQ
Classification
COMMON
Status
Historical · closed Jun 16, 2026
Filing context

Context: AsOf2026-05-07

Dimensions: Not supplied

Accession 000110465926057577 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 8, 2026, Assertio Holdings, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that on May 7, 2026, in connection with the previously announced entry into an Amended and Restated Agreement and Plan of Merger, dated as of May 1, 2026 (the “Merger Agreement”), by and among the Company, Garda Therapeutics, Inc., a Delaware corporation (“Garda”), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Garda, the Company had reached a mutual agreement with Garda to extend the deadline to commence the previously announced tender offer to purchase all of the outstanding shares of the Company’s common stock to May 14, 2026. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) tm2611405d24_ex99-1.htm

EX-99.1 2 tm2611405d24_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Assertio and Garda Mutually Agree to Delay Launch of Tender Offer LAKE FOREST, IL - May 8, 2026 - Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the “Garda Agreement”) to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026. About Assertio Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.